Astria Therapeutics, Inc. (ATXS) Financials

ATXS Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2025 271.9 million 38.6 million
June 30, 2025 281.9 million 21.4 million
March 31, 2025 310.4 million 21.1 million
Dec. 31, 2024 342.4 million 23.1 million

ATXS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2025 -32.3 million 4.3 million
June 30, 2025 -36.6 million 4.4 million
March 31, 2025 -34.0 million 3.8 million
Dec. 31, 2024 -17.4 million 3.4 million

ATXS Net Income

No data available :(

ATXS Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2025 227.7 million 3.1 million 4.5 million
June 30, 2025 259.2 million 3.4 million 4.8 million
March 31, 2025 295.1 million 3.7 million 5.1 million
Dec. 31, 2024 328.1 million 4.0 million 5.4 million

ATXS Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2025 58.0 million
June 30, 2025 58.0 million
March 31, 2025 58.0 million
Dec. 31, 2024 56.4 million

ATXS Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2025 32.3 million 24.1 million 10.7 million -
June 30, 2025 590000 25.9 million 9.9 million -
March 31, 2025 - 27.8 million 9.2 million -
Dec. 31, 2024 - 20.2 million 9.7 million 400000

ATXS Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2025 706000 -
June 30, 2025 - -
March 31, 2025 - -
Dec. 31, 2024 - -

ATXS

Price: $12.58

52 week price:
3.56
13.29

Earnings Per Share: -2.14 USD

P/E Ratio: -5.99

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 121600

Market Capitalization: 731.8 million

Links: